| Term | Definition |
|---|
| PUD risk factors | NSAID, H.pylori, -corticosteroids(mainly if used with nsaids) |
| Mechanism of mucosal damage by nsaids | systemic inhibition of gi prostaglandin synthesis -wc is needed to maintain blood flow ,-stimulate bicarbonate and mucus production |
| H.pylori treatment(triple tx)ppi triple therapy | ppi bid + clarithromycin + amoxicillin/metronidazole |
| H.pylori tx(Bismuth triple therapy) | Bismuth+metronidazole+tetracycline |
| H.pylori resistant case(quadrupule tx) | ppi bid+bismuth+metronidazole+tetracycline |
| Gerd therapy(phase 1) | Lifestyle changes +antacids(Maalox) and or low dose otc h2 receptors(cimetidine) or otc ppi(osmeprazole). |
| Gerd therapy(After 2 weeks(phase 11) | H2 receptors anatagonists (cimetidine) or ppi(osmeprazole) |
| what is PUd approach to treatment? | use of non-acetylated salicylates,etodolac or selective COX-2 inhibitors |
| Pharmacotherapeutic options(gerd) | Antacid,h2 receptors ,Ppi |
| Pharmacotherapeutic options(pud) | h2 receptors, Ppi,sucrlfate,Misoprostol,Metoclopramide |
Combine with other sets
Share on Facebook
Share on MySpace
!